Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genicular artery embolization with imipenem/cilastatin versus microspheres for chronic knee pain
RBR-2h5rwgbPhase 4Completed
- Sponsor
- InVasc Therapeutics, Inc.
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of imipenem + cilastatin in knee osteoarthritis (OA) (2 arms), sponsored by InVasc Therapeutics, Inc. Primary endpoint: Pain improvement. Started Feb 2021; status: completed.
02
Drugs
imipenem + cilastatin
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on RBR-2h5rwgb.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-2h5rwgb.